• ACE inhibitors and ARBs have shown survival benefit in patients with chronic heart failure. • Sacubitril is a neprilysin inhibitor, which synergizes with RAS blockade by inhibiting breakdown of vasoactive peptides. • Sacubitril–Valsartan combination (LCZ696) has shown additional survival benefit when compared with ACE inhibitor enalapril alone. Sacubitril–Valsartan combination coded “LCZ696” successfully completed a […]